Anand Reddy, MD
Nephrology · Odessa, TXNPI 1780892760
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $345,031 of the $468,774 with a category attached, or 73.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.7%. 2025 is the largest year on record at $163,301, 4.7 times the $34,822 reported in 2019. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 975 payments — averaging $480.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$97K
- Amgen$93K
- AstraZeneca$76K
- Travere Therapeutics, Inc.$41K
- Lilly USA, LLC$33K
- Akebia Therapeutics Inc$24K
- plus $105K from 25 others
Across 7 payments — averaging $11,836 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$80K
- Eli Lilly$2K
What the payments were for
- Consulting fees$14,4203%
- Speaking & faculty fees$345,03174%
- Travel & lodging$90,71419%
- Food & beverage$18,5054%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 98 | $97,228 |
| Amgen(2 entities) | 146 | $92,929 |
| AstraZeneca(2 entities) | 152 | $75,542 |
| Travere Therapeutics, Inc. | 104 | $40,913 |
| Lilly USA, LLC | 37 | $32,709 |
| Akebia Therapeutics Inc | 36 | $24,048 |
| Fresenius USA Marketing, Inc. | 42 | $21,738 |
| Ardelyx, Inc. | 23 | $19,709 |
| Vifor Pharma, Inc. | 66 | $19,666 |
| Boehringer Ingelheim | 63 | $17,520 |
| Scpharmaceuticals Inc. | 17 | $9,955 |
| ANI Pharmaceuticals, Inc. | 14 | $9,150 |
| American Regent | 1 | $4,160 |
| OPKO Pharmaceuticals, LLC | 80 | $1,268 |
| Otsuka America Pharmaceutical, Inc. | 18 | $400 |
| Bayer | 14 | $325 |
| GSK | 11 | $238 |
| Aurinia Pharma U.S., Inc. | 10 | $210 |
| Novartis | 6 | $188 |
| Lexicon Pharmaceuticals, Inc. | 11 | $179 |
| Mallinckrodt Hospital Products Inc. | 11 | $178 |
| Outset Medical Inc | 2 | $93 |
| Shire North American Group Inc | 1 | $89 |
| Genentech USA, Inc. | 4 | $71 |
| AbbVie | 1 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $51 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Baxter Healthcare | 2 | $35 |
| Sanofi | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$96,351
- Tavneos$91,748
- LOKELMA$70,895
- JARDIANCE$41,452
- Filspari$34,452
- Vafseo$21,688
- Velphoro$20,842
- XPHOZAH 30 MG$19,506
- Veltassa$18,852
- FUROSCIX$9,644
- PURIFIED CORTROPHIN GEL$8,888
- Trace Elements 4$4,160
- FARXIGA$2,475
- AURYXIA$1,755
- OPTIFLUX$155
- BENLYSTA$125
How this compares
$468,774 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 122 | $417,289 |
| RayaldeeCalcifediol | 259 | $338,333 |
| TavneosAvacopan | 12 | $199,038 |
| JardianceEmpagliflozin | 268 | $195,261 |
| FarxigaDapagliflozin Propanediol | 113 | $87,860 |
| VeltassaPatiromer Calcium Sorbitex | 64 | $78,134 |
| MounjaroTirzepatide | 71 | $77,433 |
| OzempicSemaglutide | 53 | $58,705 |
| XphozahTenapanor Hcl | 21 | $58,362 |
| ProcritEpoetin Alfa | 90 | $57,405 |
| LokelmaSodium Zirconium Cyclosilicate | 53 | $50,387 |
| Sevelamer Carbonate | 163 | $41,801 |
| KerendiaFinerenone | 56 | $40,882 |
| TradjentaLinagliptin | 58 | $29,337 |
| AuryxiaFerric Citrate | 19 | $28,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $21,738 | $417,289122 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,268 | $338,333259 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17,520 | $224,598326 claims |
| AmgenTavneos | $92,929 | $199,03812 claims |
| AstraZenecaFarxiga, Lokelma | $75,542 | $138,247166 claims |
| Lilly USA, LLCMounjaro | $32,709 | $77,43371 claims |
| Johnson & JohnsonProcrit | $20 | $57,40590 claims |
| BayerKerendia | $325 | $40,88256 claims |
| Akebia Therapeutics IncAuryxia | $24,048 | $28,75019 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $179 | $7,19112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Odessa
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Saravanan BalamuthusamyFort Worth$435K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.